Start with the product, then the purpose
A clinic may use the words prescription, personalized and off-label in the same conversation. Those words do not answer the same question. The first question is what product will actually be dispensed. The second is what condition it is intended to treat. FDA explains that an approved medicine can be prescribed for a use outside its labeling when a clinician judges that medically appropriate. That does not mean FDA has evaluated the new use. [1]
For a consumer comparing peptide care, this distinction changes what to request. Ask for the medicine's exact name, formulation, manufacturer or compounder, and the proposed purpose. A reference to the active ingredient alone leaves too much unresolved. A branded injection and a customized preparation can share a molecule name while differing in formulation and regulatory status. A prescription confirms that a prescriber was involved; it is not an approval certificate for the item that arrives.
Why a compounded preparation needs its own explanation
FDA says compounded medicines are not FDA-approved and are not the same as FDA-approved generic drugs. Compounding can meet a medical need when an approved product is unsuitable, but it does not receive the premarket review used for an approved medicine. Biological products have a separate framework and are not eligible for the statutory compounding exemptions. [2]
Our practical reading is that a clinic should explain why the particular preparation is being proposed for the particular patient. A general statement that the ingredient has been studied is insufficient to establish that the preparation has the same clinical evidence. Likewise, a paper about a branded product should not be presented as a direct trial of every preparation bearing its ingredient name. This is an evidence-matching question before it is a pricing question.
A practical way to read the claim
Suppose a provider says its treatment uses an ingredient studied in an approved medicine. There are at least four separate claims hidden in that sentence: the ingredient identity, the finished product, the intended use and the evidence being cited. Ask the provider to name each one. If only the ingredient matches, describe the evidence as indirect for the finished preparation. If the product matches but the intended use differs, ask what supports that use. If the product and use both match, read the labeling and the full quote anyway; approval does not settle affordability or personal suitability.
The same discipline applies when an offer uses a familiar brand as a comparison. A phrase such as alternative to can mean a similar commercial purpose without establishing pharmaceutical equivalence. Ask whether the provider is naming an approved generic, an approved brand or a compounded preparation. Do not infer the answer from a website photograph or a colloquial product nickname. The prescribing and dispensing records should identify the medicine more precisely than the advertisement does.
This is why our pharmacy framework guide treats facility status separately, while the trial relevance guide treats clinical generalization separately. A third question is the outcome: biomarkers and benefits explains why an observed biological change may be narrower than a promised result. Taken together, these checks help a reader identify exactly where additional evidence or clinical judgment is being used.
If the explanation remains unclear, ask for it in writing before choosing a longer commitment. A useful response can acknowledge uncertainty. An unsupported guarantee cannot remove uncertainty, and a confident sales description cannot supply a missing study. The aim is a precise conversation about the product being offered, the goal being pursued and the reasonable alternatives available for that goal.
Read a tesamorelin example carefully
Egrifta WR is labeled for reducing excess abdominal fat in adults with HIV and lipodystrophy. Its label says it is not indicated for weight-loss management. It also distinguishes its own formulation from Egrifta SV. [3] Those details make a useful reading exercise: identify the product, population, outcome and formulation before interpreting an advertisement about a broader longevity goal.
If an offer uses the molecule name tesamorelin, do not assume that it refers to Egrifta WR or that the labeled indication matches your reason for asking. Request the label that applies to the item being prescribed. A clinician can discuss the evidence for a proposed use, alternatives and monitoring. This article cannot establish that an unnamed product is lawful, clinically suitable or equivalent to the brand.
Separate permission, evidence and affordability
Three decisions often get compressed into one. Whether a clinician may consider a use is a regulatory question. Whether the evidence supports a worthwhile benefit for someone like you is a clinical question. Whether the total bill is acceptable is a financial question. A favorable answer to any one does not settle the others. Keep a short written record of the answer to each before comparing providers.
For example, a lower monthly quote does not answer whether a trial enrolled a relevant patient group. A familiar pharmacy name does not show that a proposed treatment improves the outcome that matters to you. An impressive biomarker change does not establish better daily functioning. Asking these separately makes a consultation more useful and prevents a comparison table from carrying conclusions its underlying facts cannot support.
Bring specific questions to the consultation
Ask what the exact product is approved for, what evidence supports the proposed use, and what uncertainty remains. Ask which approved alternatives could address the same problem and how the provider would decide whether treatment should continue. Request an explanation in ordinary language if the answer relies on a hormone level rather than a patient outcome. You do not need to interpret every laboratory value to ask for that distinction.
Then use the plan inclusion checklist to clarify the separate commercial terms: visits, labs, medication, delivery and cancellation. Record unanswered questions in the provider shortlist. These tools organize a conversation; their output does not establish treatment eligibility or recommend a prescription.
Three questions for a product-specific discussion
A useful discussion can begin with three separate questions. First, what is the precise product: an approved brand, an approved generic, or a compounded preparation? Second, what condition or goal is being considered? Third, which evidence supports that combination of product and use? Keeping those questions separate prevents a familiar ingredient name from doing more work than the evidence supports. FDA describes off-label use as use of an approved drug outside its approved labeling [1].
For example, a published trial of an approved injectable medicine does not establish that a differently prepared nasal product has the same absorption, effects or safety. A clinician may have a reason for proposing a preparation, but that explanation and its uncertainties should be stated directly. Ask whether the cited evidence concerns the actual route, formulation and patient group. A prescription requirement is one feature of appropriate care; it is not a substitute for product approval.
Write down the answers before comparing providers. If the product identity is unresolved, keep it unresolved in the comparison instead of checking an approved box. If the use differs from the study, record that difference and ask what additional evidence bridges the gap. The result is a clearer decision conversation without assuming that either a prescription or an approval label answers every question.
A primary study shows the boundary of the claim
For a concrete example, the pivotal tesamorelin trial randomized 412 adults with HIV and abdominal fat accumulation for 26 weeks. Visceral fat decreased 15.2% with tesamorelin versus a 5.0% increase with placebo [4]. Those are results for the studied intervention and population. They cannot establish that a compounded preparation is approved, or that a different peptide produces the same effect. Product approval and evidence for a particular proposed use therefore remain separate questions.